Deferred Tax Assets, Operating Loss Carryforwards of KalVista Pharmaceuticals, Inc. from 31 Dec 2013 to 30 Apr 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
KalVista Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2013 to 30 Apr 2025.
  • KalVista Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Apr 2025 was $54,638,000, a 8.9% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $54,638,000 +$4,459,000 +8.9% 30 Apr 2025 10-K 10 Jul 2025 2025 FY
Q1 2024 $50,179,000 +$14,389,000 +40% 30 Apr 2024 10-K 10 Jul 2025 2025 FY
Q1 2023 $35,790,000 +$12,571,000 +54% 30 Apr 2023 10-K 11 Jul 2024 2024 FY
Q1 2022 $23,219,000 +$8,809,000 +61% 30 Apr 2022 10-K 10 Jul 2023 2023 FY
Q1 2021 $14,410,000 +$7,043,000 +96% 30 Apr 2021 10-K 07 Jul 2022 2022 FY
Q1 2020 $7,367,000 -$57,000 -0.77% 30 Apr 2020 10-K 13 Jul 2021 2021 FY
Q1 2019 $7,424,000 +$828,000 +13% 30 Apr 2019 10-K 01 Jul 2020 2020 FY
Q1 2018 $6,596,000 +$994,000 +18% 30 Apr 2018 10-K 16 Jul 2019 2019 FY
Q1 2017 $5,602,000 +$2,846,000 +103% 30 Apr 2017 10-K 30 Jul 2018 2018 FY
Q1 2016 $2,756,000 30 Apr 2016 10-K 27 Jul 2017 2017 FY
Q4 2015 $26,916,000 +$9,477,000 +54% 31 Dec 2015 10-K 30 Mar 2016 2015 FY
Q4 2014 $17,439,000 +$4,228,000 +32% 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q4 2013 $13,211,000 31 Dec 2013 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.